Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has appointed Moncef Slaoui, PhD, to its ...

Enhancing its peptide synthesis capabilities to meet increasing demand from its global partners for efficient and scalable ...

Esphera SynBio, a pre-clinical stage synthetic biology company, has launched a new project aimed at enhancing the efficacy of ...

Grants Verdiva Bio exclusive global rights (excluding Greater China and South Korea) to develop and commercialize its ...

Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...

The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Chime Biologics, a global CDMO, and Mabgeek, a clinical-stage innovative antibody drug development biotech, have successfully ...

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, has appointed Lori ...

Veeda Group has unveiled a new logo and brand identity— Veeda Lifesciences —reflecting the brand’s evolution from a ...

Sangamo plans to explore all options to commercialize the Hemophilia A asset.

Becomes the first subcutaneously administered PD-1 inhibitor.

With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...